These results show that EA inhibited RCC cell migration and invasion by downregulating RUNX2 targeting MMP1 expression, and clinical evidence suggests that the level of RUNX2 expression may be prognostic factor for RCC. This evidence concerns the gene RUNX2 and renal cell carcinoma.